Reversible skin and hair depigmentation during chemotherapy with dasatinib for chronic myeloid leukemia

Journal of Dermatology

Volumn 43, Issue 1, 2016, Pages 106-107

  Fujimi, Akihito ^a   Ibata, Soushi ^a   Kanisawa, Yuji ^b   Shibata, Takanori ^b   Sakamoto, Hiroki ^b   Yamada, Shota ^b   Okuda, Toshinori ^b   Takahashi, Sho ^b   Minami, Shinya ^b   Hashimoto, Akari ^c  

^a Oji General Hospital   (Japan)

^b Oji General Hospital   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOSUTINIB; DASATINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADULT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DEPIGMENTATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LETTER; MIDDLE AGED; PLEURA EFFUSION; SKIN PIGMENTATION; DRUG EFFECTS; HAIR COLOR; LEUKEMIA, MYELOID, ACCELERATED PHASE; PIGMENTATION;

ANTINEOPLASTIC AGENTS; DASATINIB; FEMALE; HAIR COLOR; HUMANS; LEUKEMIA, MYELOID, ACCELERATED PHASE; MIDDLE AGED; PIGMENTATION; PROTEIN KINASE INHIBITORS; SKIN PIGMENTATION;

EID: 84946221125     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13150     Document Type: Letter

References (5)

1. Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME,. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer 2008; 16: 557-566.
2. Boudadi K, Chugh R,. Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinib. J Clin Diagn Res 2014; 8: QD01-QD02.
3. Brazzelli V, Grasso V, Barbaccia V, et al,. Hair depigmentation and vitiligo-like lesions in a leukaemic paediatric patient during chemotherapy with dasatinib. Acta Derm Venereol 2012; 92: 218-219.
4. Sun A, Akin RS, Cobos E, Smith J,. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor. J Drugs Dermatol 2009; 8: 395-398.
5. Samimi S, Chu E, Seykora J, et al,. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 2013; 149: 637-639.